Clinical Trial Update: Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating injections of OLP-1002 to reduce moderate-to-severe hip and/or knee osteoarthritis pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• OLP-1002 (OLP-1002)

Snippet

Sponsor: OliPass Corporation | Conditions: Osteoarthritis | Phase 2 | Status: COMPLETED